Skip to main content
Premium Trial:

Request an Annual Quote

EnPlusOne Biosciences Nabs Exclusive License to RNA Synthesis Technology from Wyss Institute

NEW YORK – EnPlusOne Biosciences said on Monday that it has exclusively licensed enzymatic RNA oligonucleotide synthesis technology from the Wyss Institute at Harvard University.

EnPlusOne Bio has secured a worldwide license to commercialize the ezRNA platform developed in the lab of George Church, one of the firm's cofounders. The technology uses a water-based synthesis, rather than chemical solvents.

Church and other cofounders applied for a US patent titled "Enzymatic RNA Synthesis" in October 2019.

Financial and other terms of the deal were not disclosed.

"We will be building out a pilot lab over the next two years and expanding the capabilities of the technology," CEO and Cofounder Daniel Wiegand said in a statement.

The Watertown, Massachusetts-based startup launched in October with $12 million in seed funding, led by Northpond Labs.

EnPlusOne Bio is one of the latest in a long line of startups to come out of the Church lab. Other spinouts include ReadCoor, which was acquired by 10x Genomics in 2020 for $350 million, and Gen9, a DNA synthesis startup acquired by Ginkgo Bioworks in 2017 for an undisclosed amount.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.